Two Sigma Advisers’s TRACON Pharmaceuticals TCON Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-515
Closed -$19.5K – 2722
2023
Q1
$19.5K Sell
515
-2,145
-81% -$70.3K ﹤0.01% 2520
2022
Q4
$79.3K Sell
2,660
-2,375
-47% -$71.8K ﹤0.01% 2322
2022
Q3
$168K Sell
5,035
-2,990
-37% -$114K ﹤0.01% 2236
2022
Q2
$321K Sell
8,025
-2,425
-23% -$93.9K ﹤0.01% 2093
2022
Q1
$550K Sell
10,450
-6,150
-37% -$309K ﹤0.01% 1936
2021
Q4
$920K Sell
16,600
-1,790
-10% -$114K ﹤0.01% 1603
2021
Q3
$1.42M Buy
18,390
+4,185
+29% +$354K ﹤0.01% 1435
2021
Q2
$1.84M Sell
14,205
-1,165
-8% -$161K ﹤0.01% 1328
2021
Q1
$2.53M Buy
15,370
+2,685
+21% +$517K 0.01% 1155
2020
Q4
$2.97M Buy
+12,685
New +$1.77M 0.01% 1067
2020
Q3
– Sell
-2,770
Closed -$109K – 2678
2020
Q2
$109K Buy
2,770
+2,120
+326% +$83.9K ﹤0.01% 2346
2020
Q1
$22K Buy
+650
New +$37.8K ﹤0.01% 2411

Other funds holding TCON

Two Sigma Advisers's TCON Position: Q2 2023 in Review

Two Sigma Advisers sold out of TRACON Pharmaceuticals (TCON) in Q2 2023, closing a stake of 515 shares — an estimated $19.5K sold.

Two Sigma Advisers first reported a position in TCON in Q1 2020 and held it in 12 quarters. The position peaked at $2.97M in Q4 2020. 27 funds tracked by Wall St. Rank hold TCON as of Q2 2023.

  • Two Sigma Advisers reported no remaining TRACON Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Two Sigma Advisers sold 515 TRACON Pharmaceuticals shares in Q2 2023, an estimated $19.5K.
  • Two Sigma Advisers first reported a position in TRACON Pharmaceuticals in Q1 2020 and held it in 12 quarters.
  • Two Sigma Advisers's TRACON Pharmaceuticals position peaked at $2.97M in Q4 2020.
  • 27 funds tracked by Wall St. Rank held TRACON Pharmaceuticals as of Q2 2023.

Based on Two Sigma Advisers's 13F filing for Q2 2023, filed 14 Aug 2023.